Publication
Genome-wide association study of cardiovascular disease in testicular cancer patients treated with platinum-based chemotherapy
Steggink, L. C., Boer, H., Meijer, C., Lefrandt, J. D., Terstappen, L. W. M. M., Fehrmann, R. S. N. & Gietema, J. A., 3-Oct-2020, In : Pharmacogenomics journal. 13 p.Research output: Contribution to journal › Article › Academic › peer-review
APA
Author
Harvard
Standard
Genome-wide association study of cardiovascular disease in testicular cancer patients treated with platinum-based chemotherapy. / Steggink, Lars C; Boer, Hink; Meijer, Coby; Lefrandt, Joop D; Terstappen, Leon W M M; Fehrmann, Rudolf S N; Gietema, Jourik A.
In: Pharmacogenomics journal, 03.10.2020.Research output: Contribution to journal › Article › Academic › peer-review
Vancouver
BibTeX
}
RIS
TY - JOUR
T1 - Genome-wide association study of cardiovascular disease in testicular cancer patients treated with platinum-based chemotherapy
AU - Steggink, Lars C
AU - Boer, Hink
AU - Meijer, Coby
AU - Lefrandt, Joop D
AU - Terstappen, Leon W M M
AU - Fehrmann, Rudolf S N
AU - Gietema, Jourik A
PY - 2020/10/3
Y1 - 2020/10/3
N2 - Genetic variation may mediate the increased risk of cardiovascular disease (CVD) in chemotherapy-treated testicular cancer (TC) patients compared to the general population. Involved single nucleotide polymorphisms (SNPs) might differ from known CVD-associated SNPs in the general population. We performed an explorative genome-wide association study (GWAS) in TC patients. TC patients treated with platinum-based chemotherapy between 1977 and 2011, age ≤55 years at diagnosis, and ≥3 years relapse-free follow-up were genotyped. Association between SNPs and CVD occurrence during treatment or follow-up was analyzed. Data-driven Expression Prioritized Integration for Complex Trait (DEPICT) provided insight into enriched gene sets, i.e., biological themes. During a median follow-up of 11 years (range 3-37), CVD occurred in 53 (14%) of 375 genotyped patients. Based on 179 SNPs associated at p ≤ 0.001, 141 independent genomic loci associated with CVD occurrence. Subsequent, DEPICT found ten biological themes, with the RAC2/RAC3 network (linked to endothelial activation) as the most prominent theme. Biology of this network was illustrated in a TC cohort (n = 60) by increased circulating endothelial cells during chemotherapy. In conclusion, the ten observed biological themes highlight possible pathways involved in CVD in chemotherapy-treated TC patients. Insight in the genetic susceptibility to CVD in TC patients can aid future intervention strategies.
AB - Genetic variation may mediate the increased risk of cardiovascular disease (CVD) in chemotherapy-treated testicular cancer (TC) patients compared to the general population. Involved single nucleotide polymorphisms (SNPs) might differ from known CVD-associated SNPs in the general population. We performed an explorative genome-wide association study (GWAS) in TC patients. TC patients treated with platinum-based chemotherapy between 1977 and 2011, age ≤55 years at diagnosis, and ≥3 years relapse-free follow-up were genotyped. Association between SNPs and CVD occurrence during treatment or follow-up was analyzed. Data-driven Expression Prioritized Integration for Complex Trait (DEPICT) provided insight into enriched gene sets, i.e., biological themes. During a median follow-up of 11 years (range 3-37), CVD occurred in 53 (14%) of 375 genotyped patients. Based on 179 SNPs associated at p ≤ 0.001, 141 independent genomic loci associated with CVD occurrence. Subsequent, DEPICT found ten biological themes, with the RAC2/RAC3 network (linked to endothelial activation) as the most prominent theme. Biology of this network was illustrated in a TC cohort (n = 60) by increased circulating endothelial cells during chemotherapy. In conclusion, the ten observed biological themes highlight possible pathways involved in CVD in chemotherapy-treated TC patients. Insight in the genetic susceptibility to CVD in TC patients can aid future intervention strategies.
KW - LONG-TERM SURVIVORS
KW - METABOLIC SYNDROME
KW - CISPLATIN
KW - EXPRESSION
KW - NEPHROTOXICITY
KW - ACTIVATION
KW - BLEOMYCIN
KW - APOPTOSIS
KW - NECROSIS
KW - INJURY
U2 - 10.1038/s41397-020-00191-8
DO - 10.1038/s41397-020-00191-8
M3 - Article
C2 - 33011741
JO - Pharmacogenomics journal
JF - Pharmacogenomics journal
SN - 1470-269X
ER -
ID: 135326871